MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit

Shareholders with losses of $100,000 or more are encouraged to contact the firm

Los Angeles, California--(Newsfile Corp. - July 31, 2024) - Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS).

Class Period: March 17, 2021 - May 7, 2024
Lead Plaintiff Deadline: August 5, 2024

If you wish to serve as lead plaintiff of the Marinus lawsuit, you can submit your contact information at www.glancylaw.com/cases/Marinus-Pharmaceuticals-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [e-mail] to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) Defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [e-mail], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[e-mail]
www.glancylaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218396

The Marinus Pharmaceuticals Stock at the time of publication of the news with a fall of -0,77 % to 1,290EUR on Tradegate stock exchange (30. Juli 2024, 22:26 Uhr).